The cardiovascular continuum: from endothelial dysfunction to clinical events. The role of organic nitrates
Abstract
Overview
The endothelium plays a key role in the regulation of numerous physiological functions,
including fibrinolysis, thrombosis, inflammation, cell growth and the maintenance of vascular
tone. Several studies have shown that endothelial dysfunction is an early event in the
course of the heart failure and changes in vascular reactivity have a series of hemodynamic consequences,
including increases in total peripheral resistance and afterload, worsening of cardiac
performance and a reduction in tolerance to exercise.
Organic nitrates are the oldest drugs used in patients with coronary artery disease and heart failure
and are able to deliver nitric oxide (NO) directly to the vascular wall inducing the well known
vasodilator effects.
Therefore, it is likely that the release of NO by organic nitrates is associated with antiaggregatory,
antiadhesive, antiproliferative and antioxidative effects, all of which are considered to be vasoprotective.
Recent data from animal models suggest that treatment with high doses of isosorbide mononitrate
(ISMN) reduce the progression of atherosclerosis and this reduction of morphologic
changes is associated with an improvement of the endothelial function. Organic nitrates and recent
mononitrates (IS-5-MN and IS-2-MN) appear useful to protect arterial endothelium and inhibit
the progression of the disease in heart failure and ischemic heart disease. (Heart International
2007; 3: 78-85)
Keywords
Ischemic heart disease, Atherosclerosis, Heart failure, Mononitrates, Endothelial dysfunction, Vasodilation, Antioxidative effects, Vasoprotective effects
Article Information
Correspondence
Prof. Maria Grazia Modena, Cattedra di Cardiologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Via del Pozzo, 71, 41100 Modena, Italy, mariagrazia.modena@unimore.it
Further Resources
Trending Topic
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1 High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2 Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and untreated due to inadequate screening, poor awareness and lack of treatment adherence.3 Globally, HTN is undiagnosed in about 46% […]
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1Â High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2Â Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and ...
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1Â Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1Â Recent estimates suggest that over 40% ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
...
...
...
...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
